The pathogenesis of LAM is closely linked to mutations in the tuberous sclerosis complex (TSC) genes, TSC1 and TSC2 genes, which encode hamartin and tuberin, respectively, critical components of the mammalian target of rapamycin pathway (mTOR) signaling pathway [1]. Here, TSC1 is linked to lymphangioleiomyomatosis.